Literature DB >> 10818533

Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease?

J C de la Torre1.   

Abstract

After nearly a century of inquiry, the cause of sporadic Alzheimer's disease (AD) remains to be found. On the subject of AD pathogenesis, recent basic and clinical evidence strongly argues in favor of the concept that AD is linked to brain circulatory pathology. This concept, when viewed from many different medical disciplines and from close pre-morbid similarities to vascular dementia, assembles and hypothetically explains most of the key pathologic events associated with the development of AD. These pathologic events are triggered in AD by impaired cerebral perfusion originating in the microvasculature which affects the optimal delivery of glucose and oxygen and results in an energy metabolic breakdown of brain cell biosynthetic and synaptic pathways. We propose that two factors converge to initiate cognitive dysfunction and neurodegeneration as expressed in AD brain: (1) advanced aging, and (2) the presence of a condition that lowers cerebral perfusion. The first factor introduces a normal but potentially deconstructing process that lowers cerebral blood flow in proportion to increased aging, whereas the second factor adds a crucial burden that further lowers brain perfusion to a critical threshold that triggers neuronal metabolic compromise. When age and a condition that lowers cerebral perfusion converge, critically attained threshold of cerebral hypoperfusion (CATCH) results. CATCH is a cyclical and progressive cerebrovascular insufficiency that will destabilize neurons, synapses, neurotransmission, and cognitive ability, eventually evolving into a neurodegenerative process characterized by the formation of senile plaques, neurofibrillary tangles, and amyloid angiopathy. The concept of impaired cerebral perfusion as the cause of this dementia also explains the heterogeneic profile observed in AD patients, because an extensive list of risk factors for AD are also reported to significantly diminish blood flow to the aging brain.

Entities:  

Mesh:

Year:  2000        PMID: 10818533     DOI: 10.1111/j.1749-6632.2000.tb06394.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  23 in total

1.  Carotid atherosclerosis and cognitive function in midlife: the Beaver Dam Offspring Study.

Authors:  Wenjun Zhong; Karen J Cruickshanks; Guan-Hua Huang; Barbara E K Klein; Ronald Klein; F Javier Nieto; James S Pankow; Carla R Schubert
Journal:  Atherosclerosis       Date:  2011-07-20       Impact factor: 5.162

2.  Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study.

Authors:  Nabil Maalikjy Akkawi; B Borroni; C Agosti; M Magoni; M Broli; A Pezzini; A Padovani
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

3.  Lifecourse social conditions and racial and ethnic patterns of cognitive aging.

Authors:  M Maria Glymour; Jennifer J Manly
Journal:  Neuropsychol Rev       Date:  2008-09-25       Impact factor: 7.444

Review 4.  Structural brain alterations in heart failure: a review of the literature and implications for risk of Alzheimer's disease.

Authors:  Michael L Alosco; Scott M Hayes
Journal:  Heart Fail Rev       Date:  2015-09       Impact factor: 4.214

Review 5.  Effects of hypoperfusion in Alzheimer's disease.

Authors:  Benjamin P Austin; Veena A Nair; Timothy B Meier; Guofan Xu; Howard A Rowley; Cynthia M Carlsson; Sterling C Johnson; Vivek Prabhakaran
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

7.  An integrated multimodality MR brain imaging study: gray matter tissue loss mediates the association between cerebral hypoperfusion and Alzheimer's disease.

Authors:  Duygu Tosun; Norbert Schuff; Michael Weiner
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

Review 8.  Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2012-08-12       Impact factor: 3.996

9.  Prenatal stress-induced increases in hippocampal von Willebrand factor expression are prevented by concurrent prenatal escitalopram.

Authors:  Gretchen N Neigh; Christina L Nemeth; Sean D Kelly; Emily E Hardy; Chase Bourke; Zachary N Stowe; Michael J Owens
Journal:  Physiol Behav       Date:  2016-07-13

10.  Carotid atherosclerosis and 10-year changes in cognitive function.

Authors:  Wenjun Zhong; Karen J Cruickshanks; Carla R Schubert; Charles W Acher; Cynthia M Carlsson; Barbara E K Klein; Ronald Klein; Richard J Chappell
Journal:  Atherosclerosis       Date:  2012-07-25       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.